PreprintCited by 221Protein Degradation and InhibitorsChemical Synthesis and AnalysisClick Chemistry and Applications

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Efficient targeted degradation via reversible and irreversible covalent PROTACs

Open access

Gabizon, Ronen, Shraga, Amit, Gehrtz, Paul, Livnah, Ella, Gurwicz, Neta, Avram, Liat, Unger, Tamar, Albeck, Shira, Shulman, Ziv, London, Nir·2020·Journal of the American Chemical Society

DOI 10.26434/chemrxiv.11494398.v1PMC PMC7349657

Open this paper in CoChat — free account Open PDF

Abstract

PROteolysis Targeting Chimeras (PROTACs) represent an exciting inhibitory modality with many advantages, including sub-stoichiometric degradation of targets. Their scope, though, is still limited to-date by the requirement for a sufficiently potent target binder. A solution that proved useful in tackling challenging targets is the use of electrophiles to allow irreversible binding to the target. However, such binding will negate the catalytic nature of PROTACs. Reversible covalent PROTACs offer the best of both worlds. They possess the potency and selectivity associated with the formation of the covalent bond, while being able to dissociate and regenerate once the protein target is degraded. Using Bruton’s tyrosine kinase (BTK) as a clinically relevant model system, we present a proof-of concept for the first in class cyanoacrylamide reversible covalent PROTACs. We show efficient degradation with reversible covalent PROTACs, as well as their non-covalent and irreversible counterparts. The latter are amongst the most efficient PROTACs reported for BTK. They display single digit nM DC50, full degradation within 2-4 hours, proteome wide selectivity and show ~10-fold better inhibition of B cell activation than Ibrutinib. These examples refute the notion that covalent binders are not suitable as the basis for PROTACs, and may pave the way for the design of covalent PROTACs for a wide variety of challenging targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.26434/chemrxiv.11494398.v1

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
Pan, Z., Scheerens, H., Li, S., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., Mendonca, R. V., Sweeney, M. D., Scott, K. C. K., Grothaus, P. G., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200600221 · Cited by 690

Show all 39 references

Sorted by citations

Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 697
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 523
Current strategies for the design of PROTAC linkers: a critical review
Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 389
Target and tissue selectivity of PROTAC degraders
Guenette, R. G., Yang, S. W., Min, J., Pei, B., & Potts, P. R. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00200k · Cited by 324
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Zeng, S., Huang, W., Zheng, X., Cheng, L., Zhang, Z., Wang, J., & Shen, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112981 · Cited by 264
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
Bond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 232
Recent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Guo, W., Qi, X., Yu, X., Liu, Y., Chung, C.-I., Bai, F., Lin, X., Lu, D., Wang, L., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17997-6 · Cited by 228
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 222
Prey for the Proteasome: Targeted Protein Degradation—A Medicinal Chemist's Perspective
Luh, L. M., Scheib, U., Juenemann, K., Wortmann, L., Brands, M., & Cromm, P. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004310 · Cited by 201
From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
Cecchini, C., Pannilunghi, S., Tardy, S., & Scapozza, L. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.672267 · Cited by 201
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. (., et al. (2024) · Science · doi:10.1126/science.adi5798 · Cited by 175
Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies
Drummond, M. L., Henry, A., Li, H., & Williams, C. I. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00897 · Cited by 166
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Kiely‐Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 160
Bardoxolone conjugation enables targeted protein degradation of BRD4
Tong, B., Luo, M., Xie, Y., Spradlin, J. N., Tallarico, J. A., McKenna, J. M., Schirle, M., Maimone, T. J., & Nomura, D. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72491-9 · Cited by 152
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Strategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 120
Nitriles: an attractive approach to the development of covalent inhibitors
Bonatto, V., Lameiro, R. F., Rocho, F. D. R., Lameira, J., Leitão, A., & Montanari, C. A. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00204c · Cited by 125
Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy
Liu, J., Yuan, L., Ruan, Y., Deng, B., Yang, Z., Ren, Y., Li, L., Liu, T., Zhao, H., Mai, R., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01948 · Cited by 120
Lysine-Targeting Reversible Covalent Inhibitors with Long Residence Time
Reja, R. M., Wang, W., Lyu, Y., Hæffner, F., & Gao, J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c12702 · Cited by 107
Tunable Methacrylamides for Covalent Ligand Directed Release Chemistry
Reddi, R. N., Resnick, E., Rogel, A., Rao, B. V., Gabizon, R., Goldenberg, K., Gurwicz, N., Zaidman, D., Plotnikov, A. N., Barr, H. M., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10644 · Cited by 99
Self-citation
Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
Yang, F., Wen, Y., Wang, C., Zhou, Y., Zhou, Y., Zhang, Z.-M., Liu, T., & Lu, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114088 · Cited by 109
PROTAC degraders as chemical probes for studying target biology and target validation
Němec, V., Schwalm, M. P., Müller, S., & Knapp, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00478j · Cited by 98
Exploring the target scope of KEAP1 E3 ligase-based PROTACs
Du, G., Jiang, J., Henning, N. J., Safaee, N., Koide, E., Nowak, R. P., Donovan, K. A., Yoon, H., You, I., Yue, H., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.003 · Cited by 97
Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands
Zhao, H., Wang, H., Mao, Y.-Z., Zhang, H., Xin, M., Xi, X.-X., Lei, H., Mao, S., Li, D., & Zhang, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01827 · Cited by 95
An overview of kinase downregulators and recent advances in discovery approaches
Wang, B., Wu, H., Hu, C., Wang, H., Liu, J., Wang, W., & Liu, Q. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00826-7 · Cited by 93
Strategies for the discovery of oral PROTAC degraders aimed at cancer therapy
Han, X., & Sun, Y. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.101062 · Cited by 89
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Alugubelli, Y. R., Xiao, J., Khatua, K., Kumar, S., Sun, L., Ma, Y., Ma, X. R., Vulupala, V. R., Atla, S., Blankenship, L. R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02416 · Cited by 87
Site-Specific Labeling of Endogenous Proteins Using CoLDR Chemistry
Reddi, R. N., Rogel, A., Resnick, E., Gabizon, R., Prasad, P. K., Gurwicz, N., Barr, H. M., Shulman, Z., & London, N. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c06167 · Cited by 84
Self-citation
Strategic Design of Catalytic Lysine‐Targeting Reversible Covalent BCR‐ABL Inhibitors**
Quach, D., Tang, G., Anantharajan, J., Baburajendran, N., Poulsen, A., Wee, J. L. K., Retna, P., Li, R., Liu, B., Tee, D. H. Y., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202105383 · Cited by 84
Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras
Cong, T. D., Lau, J. W., Sun, C., Liu, S., Kha, T., Lim, S. T., Oon, Y. Y., Kwan, Y. P., Ma, J., Mu, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq2216 · Cited by 84
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib
Ran, F., Liu, Y., Wang, C., Xu, Z., Zhang, Y., Liu, Y., Zhao, G., & Ling, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114009 · Cited by 76
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
Tamura, T., Kawano, M., & Hamachi, I. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00745 · Cited by 75
The rise of covalent proteolysis targeting chimeras
Gabizon, R., & London, N. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.12.003 · Cited by 71
Self-citation
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Han, X., Wei, W., & Sun, Y. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0010 · Cited by 70
Recent progress in covalent warheads for in vivo targeting of endogenous proteins
Shindo, N., & Ojida, A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116386 · Cited by 69
Applications of covalent chemistry in targeted protein degradation
Lu, D., Yu, X., Lin, H., Cheng, R., Monroy, E. Y., Qi, X., Wang, M. C., & Wang, J. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00362g · Cited by 69
Targeted protein degradation in cancers: Orthodox PROTACs and beyond
Li, J., Chen, X., Lü, A., & Liang, C. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100413 · Cited by 68
Inhibitors of thiol-mediated uptake
Cheng, Y., Pham, A., Kato, T., Lim, B., Moreau, D., López‐Andarias, J., Zong, L., Sakai, N., & Matile, S. (2020) · Chemical Science · doi:10.1039/d0sc05447j · Cited by 64
Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton’s Tyrosine Kinase for the Treatment of Lymphoma
Zhang, J., Che, J., Luo, X., Wu, M., Kan, W., Jin, Y., Wang, H., Pang, A., Li, C., Huang, W., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00324 · Cited by 63
Reversible Covalent Imine-Tethering for Selective Stabilization of 14-3-3 Hub Protein Interactions
Cossar, P. J., Wolter, M., Dijck, L. V., Valenti, D., Levy, L. M., Ottmann, C., & Brunsveld, L. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03035 · Cited by 59
Translational PK–PD for targeted protein degradation
Bartlett, D. W., & Gilbert, A. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00114d · Cited by 55
Targeting Protein Kinases Degradation by PROTACs
Yu, F., Cai, M., Shao, L., & Zhang, J. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.679120 · Cited by 55
Covalent PROTACs: the best of both worlds?
Grimster, N. P. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00191d · Cited by 50
Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
McAulay, K., Bilsland, A. E., & Bon, M. (2022) · Pharmaceuticals · doi:10.3390/ph15111366 · Cited by 54
A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
Haid, R. T. U., & Reichel, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010195 · Cited by 49
Sulfamate Acetamides as Self-Immolative Electrophiles for Covalent Ligand-Directed Release Chemistry
Reddi, R. N., Rogel, A., Gabizon, R., Rawale, D. G., Harish, B., Marom, S., Tivon, B., Arbel, Y. S., Gurwicz, N., Oren, R., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08853 · Cited by 50
Self-citation
Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer
Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 49
Structure-based design of a phosphotyrosine-masked covalent ligand targeting the E3 ligase SOCS2
Ramachandran, S., Makukhin, N., Haubrich, K., Nagala, M., Forrester, B., Lynch, D. M., Casement, R., Testa, A., Bruno, E., Gitto, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41894-3 · Cited by 48
Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy
Liu, X., Xu-Liu, Pang, X., Yuan, X. Y., Yu, G.-X., Li, Y.-R., Guan, Y.-F., Zhang, Y., Song, J., Zhang, Q., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116358 · Cited by 46
Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity
Darwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 45
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Yan, J., Li, T., Miao, Z., Wang, P., Sheng, C., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00728 · Cited by 46
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules
Goebel, G. L., Qiu, X., & Wu, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.006 · Cited by 44
Degraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 45
Advanced approaches of developing targeted covalent drugs
Gai, C., Harnor, S. J., Zhang, S., Cano, C., Zhuang, C., & Zhao, Q. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00216g · Cited by 44
Reversible Dual-Covalent Molecular Locking of the 14-3-3/ERRγ Protein–Protein Interaction as a Molecular Glue Drug Discovery Approach
Somsen, B. A., Schellekens, R. J. C., Verhoef, C. J. A., Arkin, M. R., Ottmann, C., Cossar, P. J., & Brunsveld, L. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c12781 · Cited by 42
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
Rana, S., Mallareddy, J. R., Singh, S., Boghean, L., & Natarajan, A. (2021) · Cancers · doi:10.3390/cancers13215506 · Cited by 43
Discovery of novel BTK PROTACs for B-Cell lymphomas
Zhao, Y., Shu, Y., Lin, J., Chen, Z., Xie, Q., Bao, Y., Lu, L., Sun, N., & Wang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113820 · Cited by 40
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function
Zheng, T. J., Lofurno, E. R., Melrose, A. R., Lakshmanan, H. H. S., Pang, J., Phillips, K. G., Fallon, M. E., Kohs, T. C. L., Ngo, A. T. P., Shatzel, J. J., et al. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00296.2020 · Cited by 42
Protein–protein interactions: developing small-molecule inhibitors/stabilizers through covalent strategies
Lucero, B., Francisco, K. R., Liu, L. J., Caffrey, C. R., & Ballatore, C. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.007 · Cited by 40
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 48
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
Covalent Proximity Inducers
London, N. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00570 · Cited by 37
Self-citation
An Exploration of Chemical Properties Required for Cooperative Stabilization of the 14-3-3 Interaction with NF-κB—Utilizing a Reversible Covalent Tethering Approach
Wolter, M., Valenti, D., Cossar, P. J., Hristeva, S., Levy, L. M., Genski, T., Hoffmann, T., Brunsveld, L., Tzalis, D., & Ottmann, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00401 · Cited by 38
PROTAC: targeted drug strategy. Principles and limitations
Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 38
Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma
Lu, X., Sabbasani, V. R., Amponsa, V. O., Evans, C. N., King, J. C., Tarasov, S. G., Dyba, M., Das, S., Chan, K. C., Schwieters, C. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27570-4 · Cited by 35
A simple method for developing lysine targeted covalent protein reagents
Gabizon, R., Tivon, B., Reddi, R. N., van den Oetelaar, M. C. M., Amartely, H., Cossar, P. J., Ottmann, C., & London, N. (2023) · Nature Communications · doi:10.1038/s41467-023-42632-5 · Cited by 37
Self-citation
High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics
Simard, J. R., Lee, L., Vieux, E. F., Improgo, R., Tieu, T. N., Phillips, A. J., Fisher, S. L., Pollock, R. M., & Park, E. Y. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220985049 · Cited by 33
Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2
Grifagni, D., Lenci, E., Santis, A. D., Orsetti, A., Barracchia, C. G., Tedesco, F., Puglielli, R. B., Lucarelli, F., Lauriola, A., Assfalg, M., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00498 · Cited by 33
Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency
Chaudhry, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02076 · Cited by 35
A covalent BTK ternary complex compatible with targeted protein degradation
Schiemer, J. S., Maxwell, A., Horst, R., Liu, S., Uccello, D. P., Borzilleri, K. A., Rajamohan, N., Brown, M. F., & Calabrese, M. F. (2023) · Nature Communications · doi:10.1038/s41467-023-36738-z · Cited by 30
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
Unleashing the Power of Covalent Drugs for Protein Degradation
Fu, M., Jin, H., Wang, S., Shen, L., Liu, H., Liu, Y., Zheng, Y., & Dai, X. (2025) · Medicinal Research Reviews · doi:10.1002/med.22101 · Cited by 31
T herapeutic targeting of chromatin: status and opportunities
Siklos, M. I., & Kubicek, S. (2021) · FEBS Journal · doi:10.1111/febs.15966 · Cited by 28
Design of next-generation covalent inhibitors: Targeting residues beyond cysteine
Jones, L. H. (2020) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2020.10.001 · Cited by 28
Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
Yuan, M., Chu, Y., & Duan, Y. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.691093 · Cited by 27
Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads
Bálint, D., Póti, Á. L., Alexa, A., Sok, P., Albert, K., Torda, L., Földesi-Nagy, D., Csókás, D., Turczel, G., Imre, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52573-2 · Cited by 30
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 28
Innovative design and potential applications of covalent strategy in drug discovery
Tang, T., Luo, J., Zhang, D., Lü, Y., Liao, W., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117202 · Cited by 27
Targeted Degradation of ZBP1 with Covalent PROTACs for Anti‐Inflammatory Treatment of Infections
Huang, R., Hu, Y., Wang, Y., Zhang, S., Wang, Z., Pang, D., & Liu, S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202423524 · Cited by 28
The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
Coll-Martínez, B., Delgado, A., & Crosas, B. (2020) · Molecules · doi:10.3390/molecules25245956 · Cited by 28
Covalent PROTAC design method based on a sulfonyl pyridone probe
Luo, Q., Wang, Y., Hou, Z., Liang, H., Tu, L., Xing, Y., Wan, C., Liu, J., Wang, R. Y., Zhu, L., et al. (2023) · Chemical Communications · doi:10.1039/d3cc05127g · Cited by 27
Discovery of a DCAF11-dependent cyanoacrylamide-containing covalent degrader of BET-proteins
Tin, G., Cigler, M., Hinterndorfer, M., Dong, K. D., Imrichová, H., Gygi, S. P., & Winter, G. E. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129779 · Cited by 26
Mode of action of a DCAF16-recruiting targeted glue that can selectively degrade BRD9
Hughes, S. J., Stec, W. J., Davies, C. T. R., McGarry, D., Williams, A., Carrara, M., Barrantes, I. D. B., Harris, R., Tasegian, A., Owens, D. D. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63594-w · Cited by 35
Electrophilic Natural Products as Drug Discovery Tools
Gehrtz, P., & London, N. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.008 · Cited by 25
Self-citation
Advances in reversible covalent kinase inhibitors
Zhao, Z., & Bourne, P. E. (2024) · Medicinal Research Reviews · doi:10.1002/med.22084 · Cited by 26
Never Gonna Give You Up – Current Developments in Covalent Protein Kinase Inhibitors
Hillebrand, L., & Gehringer, M. (2022) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2022.435 · Cited by 24
Next-generation Bruton’s Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives
Das, D., Wang, J., & Hong, J. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220801101706 · Cited by 23
Advancing Design Strategy of PROTACs for Cancer Therapy
Luo, H., Tian, Y., Abdullah, R., Zhang, B., Ma, Y., & Zhang, G. (2025) · MedComm · doi:10.1002/mco2.70258 · Cited by 24
Technologies for Direct Detection of Covalent Protein–Drug Adducts
Mons, E., Kim, R. Q., & Mulder, M. P. C. (2023) · Pharmaceuticals · doi:10.3390/ph16040547 · Cited by 23
Solid-Phase Compatible Silane-Based Cleavable Linker Enables Custom Isobaric Quantitative Chemoproteomics
Burton, N. R., Polasky, D. A., Shikwana, F., Ofori, S., Yan, T., Geiszler, D. J., Veiga Leprevost, F. D., Nesvizhskii, A. I., & Backus, K. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05797 · Cited by 22
Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
Yu, X., Guo, W., Lin, H., Cheng, R., Monroy, E. Y., Jin, F., Ding, L., Lu, D., Qi, X., Wang, M. C., et al. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100029 · Cited by 23
Dynamic Covalent Michael Acceptors to Penetrate Cells: Thiol‐Mediated Uptake with Tetrel‐Centered Exchange Cascades, Assisted by Halogen‐Bonding Switches
Shybeka, I., Maynard, J. R. J., Saidjalolov, S., Moreau, D., Sakai, N., & Matile, S. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202213433 · Cited by 20
A Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins
Gama-Brambila, R. A., Chen, J., Dabiri, Y., Tascher, G., Němec, V., Münch, C., Song, G., Knapp, S., & Cheng, X. (2021) · JACS Au · doi:10.1021/jacsau.1c00007 · Cited by 21
Recent advances in the design of small molecular drugs with acrylamides covalent warheads
Liang, L., Zhang, Z., You, Q., & Guo, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117902 · Cited by 20
A prospective therapeutic strategy: GPX4-targeted ferroptosis mediators
Qian, J.-Y., Lou, C.-Y., Chen, Y., Ma, L., Hou, W., & Zhan, Z. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117015 · Cited by 20

Authors: Gabizon, R., Shraga, A., Gehrtz, P., Livnah, E., Gurwicz, N., Avram, L., Unger, T., Albeck, S., Shulman, Z., & London, N.
Affiliations: Weizmann Institute of Science (IL)
Corresponding author: London, Nir
ORCID: Gabizon, Ronen
Shraga, Amit
Gurwicz, Neta
Avram, Liat
Unger, Tamar
Albeck, Shira
Shulman, Ziv
London, Nir
Venue: Journal of the American Chemical Society
Publisher: American Chemical Society (ACS)
Published: 2020-01-08
Volume: 142
Issue: 27
Pages: 11734-11742
ISSN: 0002-7863 (ISSN-L)
DOI: 10.26434/chemrxiv.11494398.v1
PMC: PMC7349657
OpenAlex: W3021210206
Cited by: 213
References: 39
Citations by year: 2026: 29 · 2025: 30 · 2024: 34 · 2023: 26 · 2022: 42 · 2021: 34 · 2020: 18
FWCI: 10.22
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: Journal of the American Chemical Society (publishedVersion, cc-by)
ChemRxiv (acceptedVersion, cc-by)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Figshare (submittedVersion, cc-by)
Funders: Israel Cancer Research Fund
Weizmann Institute of Science
Ministry of Aliyah and Immigrant Absorption
Israel Cancer Association
Israel Science Foundation (2462/19, 1707/19)
Tel Aviv University
Ministry of Science and Technology, Israel (3-14763)
Rising Tide Foundation
Helen and Martin Kimmel Center for Molecular Design, Weizmann Institute of Science
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
Keywords: PROTACs, targeted protein degradation, Bruton's tyrosine kinase, chronic lymphocytic leukemia, ibrutinib

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficient targeted degradation via reversible and irreversible covalent PROTACs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks